MARKET

DMAC

DMAC

Diamedica Therapeutics Inc
NASDAQ
8.78
+0.15
+1.74%
After Hours: 9.05 +0.27 +3.08% 19:19 12/05 EST
OPEN
8.66
PREV CLOSE
8.63
HIGH
8.96
LOW
8.61
VOLUME
240.76K
TURNOVER
--
52 WEEK HIGH
9.23
52 WEEK LOW
3.190
MARKET CAP
457.24M
P/E (TTM)
-12.2386
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at DMAC last week (1124-1128)?
Weekly Report · 4d ago
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga · 11/28 21:06
Weekly Report: what happened at DMAC last week (1117-1121)?
Weekly Report · 11/24 09:35
3 Biotech Stocks Wall Street Analysts Predict Will More Than Double
Barchart · 11/20 12:50
Buy Rating Affirmed for Diamedica Therapeutics Amid Promising DM199 Trial Progress
TipRanks · 11/17 11:25
Weekly Report: what happened at DMAC last week (1110-1114)?
Weekly Report · 11/17 09:35
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga · 11/14 21:06
Microsoft initiated, Home Depot downgraded: Wall Street’s top analyst calls
TipRanks · 11/14 14:40
More
About DMAC
DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on improving the lives of people suffering from preeclampsia (PE) and acute ischemic stroke (AIS). The Company’s lead candidate, DM199, is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality in Asia for the treatment of pre-eclampsia, acute ischemic stroke and other vascular diseases. DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1 (rhKLK1) in clinical development for preeclampsia and acute ischemic stroke. KLK1 is a serine protease enzyme that is involved in the regulation of diverse physiological processes via a molecular mechanism that increases the production of nitric oxide, prostacyclin and endothelium-derived hyperpolarizing factors. In the treatment of preeclampsia, DM199 is intended to lower blood pressure, enhance endothelial health and improve perfusion to maternal organs and the placenta.

Webull offers DiaMedica Therapeutics Inc stock information, including NASDAQ: DMAC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DMAC stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading DMAC stock methods without spending real money on the virtual paper trading platform.